

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an offer or an invitation to include an offer by any person to acquire, purchase or subscribe for securities. Potential investors should read the prospectus dated November 7, 2025 (the “**Prospectus**”) issued by Sichuan Biokin Pharmaceutical Co., Ltd. (the “**Company**”) and any supplemental prospectus to be published by the Company for detailed information about the Hong Kong Public Offering and the International Offering before deciding whether or not to invest in the Offer Shares. Unless the context requires otherwise, the capitalized terms used herein shall have the same meanings as defined in the Prospectus.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdiction. The Offer Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States. The securities may not be offered, sold, pledged or otherwise transferred within the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or (1) solely to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act and (2) outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.



**Sichuan Biokin Pharmaceutical Co., Ltd.**

**四川百利天恒藥業股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2615)**

**ANNOUNCEMENT  
UPDATE ON THE GLOBAL OFFERING  
POSTPONEMENT OF THE GLOBAL OFFERING AND THE LISTING  
AND  
REFUND OF APPLICATION MONIES FOR  
THE HONG KONG PUBLIC OFFERING**

Reference is made to the Prospectus of the Company issued on November 7, 2025.

**POSTPONEMENT OF THE GLOBAL OFFERING**

As stated in the Prospectus, dealings in the Shares on the Stock Exchange were scheduled to commence at 9:00 a.m. on Monday, November 17, 2025.

In light of the prevailing market conditions, the Company, having consulted with the Overall Coordinators, has decided that the Global Offering will be postponed and will not proceed pursuant to the Prospectus.

Accordingly, the International Underwriting Agreement relating to the International Offering will not be entered into and the Hong Kong Underwriting Agreement relating to the Hong Kong Public Offering will therefore not become unconditional.

The Company would like to express its gratitude to its prospective investors for their interest in the Company, for their support and for their positive feedback during the Global Offering.

The decision to postpone the Global Offering does not affect the Company's current business and the Company is committed to developing and growing its business. In the meantime, the Company and the Overall Coordinators are carefully assessing an updated timetable in relation to the Global Offering and the Listing.

## **REFUND OF APPLICATION MONIES**

Application monies in respect of applications made through the **White Form eIPO** service for the Hong Kong Offer Shares (including brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015%) will be refunded in full without interest.

In the case of application monies paid from a single bank account, White Form e-Refund payment instructions will be dispatched to the respective application payment bank accounts on Monday, November 17, 2025. In the case of application monies paid from multiple bank accounts, refund monies will be dispatched to the applicants' addresses specified in their relevant application in the form of refund cheques in favor of the applicant (or, in the case of joint applications, the first-named applicant) by ordinary post on or before Monday, November 17, 2025 and at the applicants' own risk.

Part of the applicant's identification document number, or, if in the case of joint applicants, part of the identification document number of the first-named applicant, provided by the applicant(s) may be printed on the refund cheque, if any. Such data would also be transferred to a third party for refund purposes. Banks may require verification of an applicant's identification document number before encashment of the refund cheque. Inaccurate completion of an applicant's identification document number may invalidate or delay encashment of the refund cheque.

If you are applying through the HKSCC EIPO channel, you are advised to contact your broker or custodian for the arrangement for the refund of the application monies. Subject to the arrangement between you and your broker or custodian and the applicable laws and regulations in Hong Kong, your broker or custodian will arrange refund to your designated bank account.

## **NO ISSUE OF SHARE CERTIFICATES**

The H Share certificates for the Offer Shares have not been issued as at the date of this announcement and will not be delivered to any applicants.

By Order of the Board  
**Sichuan Biokin Pharmaceutical Co., Ltd.**  
**Dr. Zhu Yi**  
*Chairman of the Board*

Hong Kong, November 12, 2025

*As at the date of this announcement, the Board comprises (i) Dr. Zhu Yi, Ms. Zhang Suyu, Mr. Zhuo Shi, Dr. Zhu Hai and Dr. Wan Weili as executive directors; (ii) Dr. David Guowei Wang as non-executive director; and (iii) Mr. Li Mingyuan, Dr. Xiao Geng and Dr. Dai Zewei as independent non-executive directors.*